Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...
in patients with severe disease who were still symptomatic despite standard care. The drugmaker is already carrying out a second phase 3 trial of Fasenra in CRSwNP – called ORCHID – which isn ...
Zacks.com on MSN13d
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory DiseasesGSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
The approval is based on successful trials demonstrating its efficacy and safety, positioning GSK as a leader in addressing type 2 inflammation-related diseases. More about GlaxoSmithKline GSK is ...
In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key clinical outcomes with a dosing ...
20 The phase III programme in CRSwNP includes two studies, ANCHOR-1 and ANCHOR-2. 2,3 Depemokimab is currently being evaluated in phase III trials for the treatment of other IL-5 mediated diseases, ...
LONDON - GSK plc (LSE/NYSE: LON:GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback